Colorectal Cancer _ ___________________________________________________________________________ 231. Hines RB, Barrett A, Twumasi-Ankrah P, et al. Predictors of guideline treatment nonadherence and the impact on survival in patients with colorectal cancer. J Natl Compr Canc Netw . 2015;13(1):51-60. 232. Panettiere FJ, Goodman PJ, Costanzi JJ, et al. Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group study. J Clin Oncol . 1988;6(6):947-954. 233. Franklin ME Jr, Rosenthal D, Abrego-Medina D, et al. Prospective comparison of open vs. laparoscopic colon surgery for carcinoma: five-year results. Dis Colon Rectum . 1996;39(10 Suppl):S35-S46. 234. Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs. open colectomy for colon cancer: a randomized trial. JAMA . 2002;287(3):321-328. 235. Jayarajah U, Samarasekera AM, Samarasekera DN. A study of postoperative anxiety and depression among patients with intestinal stomas. Sri Lanka J Surg . 2016;34(2):6-10. 236. Liao C, Qin Y. Factors associated with stoma quality of life among stoma patients. Int J Nurs Sci . 2014;1(2):196-201. 237. Farrell M. Smeltzer and Bares Textbook of Medical-Surgical Nursing . 4th ed. Netherlands: Wolters Kluwer Health; 2016. 238. National Institute for Health and Clinical Excellence. Colorectal Cancer. Available at https://www.nice.org.uk/guidance/ng151. Last accessed March 7, 2022. 239. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol . 2004;22(10):1797-1806. 240. Benson AB III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol . 2004;22(16):3408-3419. 241. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol . 2009;27(19):3109-3116. 242. Fujita K, Kubota Y, Ishida H, Sasaki Y. Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer. World J Gastroenterol . 2015;21(43):12234-12248. 243. Martin LK, Bekaii-Saab T. Optimizing neoadjuvant therapy for rectal cancer with oxaliplatin. J Natl Compr Canc Netw . 2013;11(3):298- 307. 244. Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol . 2012;30(16):1926- 1933. 245. Roh MS, Colangelo LH, O’Connell MJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol . 2009;27(31):5124-5130. 246. Willett CG, Badizadegan K, Ancukiewicz M, Shellito PC. Prognostic factors in stage T3N0 rectal cancer: do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum . 1999;42(2):167-173. 247. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med . 2004;351(17):1731-1740. 248. Seitz U, Bohnacker S, Seewald S, et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum . 2004;47(11):1789-1796. 249. Peng J, Chen W, Venook AP, et al. Long-term outcome of early-stage rectal cancer undergoing standard resection and local excision. Clin Colorectal Cancer . 2011;10(1):37-41. 250. Stitzenberg KB, Sanoff HK, Penn DC, Meyers MO, Tepper JF. Practice patterns and long-term survival for early-stage rectal cancer. J Clin Oncol . 2013;31(34):4276-4282. 251. Nash GM, Weiser MR, Guillem JG, et al. Long-term survival after transanal excision of T1 rectal cancer. Dis Colon Rectum . 2009;52(4):577-582. 252. Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. Cochrane Database Syst Rev . 2008;(2):CD006040. 253. Maurer CA, Renzulli P, Kull C, et al. The impact of the introduction of total mesorectal excision on local recurrence rate and survival in rectal cancer: long-term results. Ann Surg Oncol . 2011;18(7):1899-1906. 254. Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol . 2007;25(8):1014-1020. 255. Fujita S, Akasu T, Mizusawa J, et al. Postoperative morbidity and mortality after mesorectal excision with and without lateral lymph node dissection for clinical stage II or stage III lower rectal cancer (JCOG0212): results from a multicentre, randomised controlled, noninferiority trial. Lancet Oncol . 2012;13(6):616-621. 256. Knol J, Keller DS. Total mesorectal excision technique – past, present, and future. Clin Colon Rectal Surg . 2020;33(3):134-143. 257. Cagir B. Rectal Cancer Treatment and Management. Available at https://emedicine.medscape.com/article/281237-treatment. Last accessed March 7, 2022. 258. Wong R, Berry S, Spithoff K, et al. Preoperative or Postoperative Therapy for the Management of Patients with Stage II or III Rectal Cancer. Available at https://www.cancercareontario.ca/en/guidelines-advice/types-of-cancer/31891. Last accessed March 7, 2022.
Powered by FlippingBook